Advanced search
Publication Cover
International Journal of Neuroscience Volume 134, 2024 - Issue 5
Submit an article Journal homepage
126
Views
1
CrossRef citations to date
0
Altmetric
Review Article

Sublingual apomorphine in treatment of Parkinson’s disease: a review

Jennifer HislopDepartment of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USAView further author information
,
Jason MargoleskyDepartment of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USACorrespondence[email protected]
View further author information
&
Danielle S. ShpinerDepartment of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USAView further author information
Pages 474-480 | Received 24 Mar 2022, Accepted 29 Jul 2022, Published online: 24 Aug 2022

References

  • Thenganatt MA, Jankovic J. The relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord. 2016;22(1):S162–S165.
  • Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896–912.
  • Hornykiewicz O. A brief history of levodopa. J Neurol. 2010;257(Suppl 2):S249–S252.
  • Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord. 2008;23(3):S497–S508.
  • Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1976;1(7954):292–296.
  • Fahn S, Jankovic J, Hallett M. Principles and practice of movement disorders. 2nd ed. Edinburgh; New York: Elsevier/Saunders; 2011.
  • Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448–458.
  • Moore H, Shpiner DS, Luca CC. Management of motor features in advanced Parkinson’s disease. Clin Geriatr Med. 2020;36(1):43–52.
  • LeWitt PA, Hauser RA, Grosset DG, et al. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease. Mov Disord. 2016;31(9):1356–1365.
  • Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Mov Disord. 2015;30(1):80–89.
  • Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord. 2005;20(2):224–230.
  • LeWitt PA, Hauser RA, Pahwa R, SPAN-PD Study Investigators, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet Neurol. 2019;18(2):145–154.
  • Shpiner DS, Bette S, Di Luca DG, et al. CVT-301 for the treatment of Parkinson's disease. Expert Rev Neurother. 2019;19(7):603–611.
  • Caughman CY, Factor S. A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson's disease ‘OFF’ episodes. Expert Rev Neurother. 2021;21(2):169–177.
  • Carbone F, Djamshidian A, Seppi K, et al. Apomorphine for Parkinson's disease: efficacy and safety of current and new formulations. CNS Drugs. 2019;33(9):905–918.
  • Pessoa RR, Moro A, Munhoz RP, et al. Apomorphine in the treatment of Parkinson's disease: a review. Arq Neuropsiquiatr. 2018;76(12):840–848.
  • KynmobiTM (apomorphine hydrochloride). In Marlborough, MA: Sunovion Pharmaceuticals, Inc.; 2020.
  • Bilbault T, Taylor S, Walker R, et al. Buccal mucosal irritation studies of sublingual apomorphine film (APL-130277) in Syrian golden hamsters. Ther Deliv. 2016;7(9):611–618.
  • Hauser RA, Olanow CW, Dzyngel B, et al. Sublingual apomorphine (APL-130277) for the acute conversion of off to on in Parkinson's disease. Mov Disord. 2016;31(9):1366–1372.
  • Hui JS, Fox SH, Neeson W, CTH-300 Study Investigators, et al. Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "off" episodes. Parkinsonism Relat Disord. 2020;79:110–116.
  • Olanow CW, Factor SA, Espay AJ, et al. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled Phase 3 study. Lancet Neurol. 2020;19(2):135–144.
  • Factor S, Ondo W, Isaacson S, et al. Long-term safety and efficacy of apomorphine sublingual film for “off” episodes in Parkinson’s disease. Mov Disord. 2021;36(suppl 1)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.